Life sciences researchers conduct laboratory testing, highlighting operational risks relevant to internal audit planning.

Top Risk Areas for Internal Audit Planning: Life Sciences

Adam Pajakowski, Ryan McNally, Benjamin Newton
11/6/2026

Explore five areas of emerging risks that are redefining internal audit in life sciences for 2027 and learn how teams can stay ahead in a shifting risk landscape.

Note: This article is part of a series on risk areas that internal audit teams should consider for their risk assessment and planning for and throughout 2027. Insight-specific articles cover trends in the following areas:

 

As life sciences organizations prepare for 2027, cybersecurity threats, AI, data privacy concerns, patent expirations, and regulatory changes present interconnected risks to patient safety, operations, revenue, and stakeholder trust.

Internal audit teams should consider prioritizing five areas in internal audit planning for 2027:

  • Cybersecurity: Assessments should cover risks associated with connected products, clinical platforms, manufacturing systems, and third-party relationships.
  • Patent cliffs and research and development (R&D): Revenue forecasts, pipeline assumptions, and investment decisions warrant scrutiny as organizations prepare for patent expirations and potential revenue losses.
  • Data privacy: Internal audit reviews should examine controls governing patient consent, data use, cross-border transfers, and third-party data protection.
  • AI governance, adoption, and data integrity: Key internal audit priorities include data integrity, model validation, ongoing monitoring, human oversight, and accountability for AI-related decisions.
  • Product quality and compliance: Internal audit teams can evaluate quality management systems, corrective and preventive action (CAPA) processes, change controls, validation, and oversight of external partners.

By addressing these priorities in their 2027 plans, internal audit teams can help life sciences organizations protect patients, maintain regulatory compliance, and manage risks that could affect long-term performance.

Cybersecurity and connected medical products 

Life sciences companies face growing cybersecurity risk as medical devices, digital health platforms, research systems, manufacturing environments, and sensitive data become more connected. This expanded digital footprint creates additional entry points for attacks across clinical, operational, regulatory, and commercial functions.

Cyberattacks could disrupt patient care, compromise connected devices and treatment platforms, interrupt manufacturing, or expose patient data, clinical trial information, trade secrets, and intellectual property. Potential consequences include patient harm, operational delays, recalls, litigation, regulatory scrutiny, and reputational damage.

The U.S. Food and Drug Administration’s (FDA’s) updated 2026 guidance reinforces the need to manage cybersecurity throughout the life cycle of medical devices. Organizations should strengthen governance, secure design, monitoring, vulnerability management, third-party oversight, incident response, and regulatory compliance.

Next steps for internal auditors

  • Medical device cybersecurity. Assess security across the device life cycle, from design through post-market support.
  • Clinical and digital health platforms. Review access, data integrity, availability, encryption, and monitoring controls.
  • Research and intellectual property. Evaluate protections for research systems, clinical data, and proprietary information.
  • Manufacturing and operational technology. Assess access, network segmentation, recovery, change management, and production resilience.
  • Third parties and incident response. Review vendor and cloud oversight, breach notification, response testing, and recovery planning.

Patent cliff, pipeline, and R&D portfolio risk

Major patent expirations and uncertain R&D productivity are increasing pressure on life sciences companies to replace revenue from mature products, and biopharma revenue could be significantly affected by patent expirations through 2027. Longer clinical development timelines could delay replacement products. Negotiated Medicare prices taking effect in 2027 could create additional pressure before some patents expire.

Internal audit should assess whether revenue-replacement plans rely on realistic pipeline, competitive, and commercial assumptions. It should also evaluate whether R&D, licensing, and acquisition decisions use consistent criteria and appropriately balance expected returns against the risk of delays, underperformance, and lost capital.

Next steps for internal auditors

  • Revenue-replacement plan. Test forecasts against potential pipeline delays, competitive pressures, and commercial shortfalls.
  • Portfolio investment decisions. Assess whether consistent criteria guide R&D funding, licensing, and acquisitions.
  • Decision-making data. Verify that forecasts use reliable, aligned, and timely information.

Patient, clinical, and genomic data privacy

As organizations expand use of patient, clinical, real-world, biometric, and genomic data across cloud platforms, vendor ecosystems, and AI applications, they are challenged with determining whether privacy governance has kept pace with data reuse, model development, cross-border movement, and secondary commercialization. These data types often carry heightened regulatory expectations, especially health, genetic, biometric, and inferred sensitive data under privacy regimes such as the Health Insurance Portability and Accountability Act (HIPAA), the European Union’s General Data Protection Regulation, and emerging AI rules. The U.S. Department of Health and Human Services also emphasizes minimum necessary use of protected health information under HIPAA, and the National Institute of Standards and Technology’s AI Risk Management Framework highlights the need to manage AI risks to individuals, organizations, and society.

Next steps for internal auditors

  • Privacy controls. Review consent, authorization, and lawful use of sensitive data.
  • Health data. Assess whether privacy governance keeps pace with health data use across cloud, vendor, and AI environments.
  • Third-party oversight. Assess contracts and due diligence covering data use, retention, transfers, breaches, and AI training.
  • Data flows. Validate how data moves across systems, platforms, vendors, and downstream users.

AI governance, adoption, and data integrity

By 2027, the AI risk for life sciences organizations will be less about whether AI is being used and more about whether organizations can demonstrate that its use is governed, controlled, validated, and fit for purpose as it becomes embedded across drug discovery, clinical development, diagnostics, manufacturing, and commercial operations. Biased or unrepresentative data, weak data provenance, inadequate validation, opaque third-party models, and uncontrolled model changes can produce unreliable outputs that misdirect research and development, undermine trial design or evidence, distort diagnostic or manufacturing quality decisions, generate unsupported commercial content, or expose sensitive information. Potential consequences extend from wasted investment and operational rework to regulatory scrutiny, product quality failures, patient harm, and loss of stakeholder trust.

Existing good practice guidelines (GxP) and other applicable obligations still apply when AI is introduced into regulated activities. At the same time, the FDA and the European Medicines Agency’s (EMA’s) January 2026 “Guiding Principles of Good AI Practice in Drug Development” provide an important regulatory signal for AI used across the drug and biological product life cycle by emphasizing a risk-based approach, clear context of use, data governance and documentation, appropriate model development and performance assessment, multidisciplinary expertise, human-centric design, and life cycle management. A September 2026 executive order, “Inaugurating the Era of Super Intelligence,” adds another federal policy signal by directing executive agencies to use super intelligence terminology and to develop potential legislative changes, although it does not itself alter existing regulations, which makes continued monitoring of how the FDA and other agencies implement evolving federal AI policy important for life sciences organizations.

Internal audit can add value by assessing whether management has established a complete, risk-tiered inventory of AI use cases, including embedded vendor functionality and unapproved or shadow AI, with clearly defined contexts of use and accountable business, quality, data, technology, and model owners. For higher-risk applications, audit procedures should move beyond policy review to evidence-based testing of data lineage and use rights, data quality and representativeness, training and test-data separation, validation criteria and performance, subgroup or bias testing where relevant, human oversight, and decision accountability.

Internal auditors should also evaluate whether drift, model and vendor changes, revalidation, incident escalation, corrective and preventive action, rollback or fallback procedures, and retirement are governed throughout the life cycle, and whether third-party contracts and evidence are sufficient to support the organization’s obligations.

Establishing a common control framework that maps these activities to applicable GxP requirements, FDA and EMA principles, and other relevant standards can enable internal audit to establish that AI governance exists and that AI-supported decisions remain traceable, reproducible, monitored, and accountable. These themes are also consistent with ISO/IEC 42001 expectations for defined accountability, data quality and provenance, human oversight, testing, and life cycle controls.

Next steps for internal auditors

  • Inventory. Validate a risk-tiered inventory, including vendor and shadow AI, with defined contexts of use and accountable owners.
  • AI. Move beyond policy review and test whether governance produces reliable evidence throughout the AI life cycle.
  • Data lineage. Test data lineage and rights, representativeness, train-test separation, performance criteria, bias, human oversight, and decision accountability.
  • Life cycle governance. Assess drift, changes, revalidation, incidents, CAPA, fallback, retirement, and whether vendors provide sufficient evidence.

Product quality, GxP, and regulatory compliance 

Product quality problems often begin with small control failures, such as unresolved deviations, untraceable results, or insufficiently validated changes. In complex life sciences operations, these issues can affect products, regulatory submissions, and patient safety. Internal audit should identify them early and assess whether they signal broader quality-system weaknesses.

Inspections should test how the quality system works in practice, not simply whether the right procedures exist. Exploratory questions include: “Can the company explain why a deviation occurred?” “Can it show that the CAPA addressed the underlying problem?” “Can it produce complete records quickly and explain differences between sites?” Answers to these questions can reveal whether controls are working.

For medical device manufacturers, the FDA’s Quality Management System Regulation took effect on Feb. 2, 2026. It aligns 21 CFR part 820 with ISO 13485:2016 and introduces an updated inspection process. Internal audit can use this shift as a prompt to test actual practices across sites and jurisdictions.

Technology adds another layer. Digital quality systems, automation, and AI can improve consistency and surface problems sooner, but only when the data and controls behind them can be trusted. A system change, new interface, or algorithm update can alter a validated process without making the impact obvious to users. The FDA’s January 2026 “Guiding Principles for AI in Drug Development” calls for a defined use, proportionate validation, documented data governance, and ongoing monitoring. Internal audit should ask who owns each tool and its output, how it was validated, how changes are approved, and how performance is monitored. Weaknesses here can contribute to warning letters, import alerts, recalls, delayed approvals, or supply disruption, with patient safety as the most serious consequence.

Next steps for internal auditors

  • Quality system performance. Assess whether metrics and escalations identify trends across sites and products.
  • Deviations and CAPA. Confirm root causes are identified and corrective actions prevent recurrence.
  • Changes and validation. Verify that changes are assessed, approved, validated, and monitored.
  • Data integrity. Test record reliability, access controls, audit trails, and electronic signatures.
  • External partners. Review supplier qualification, monitoring, and quality agreements.
  • Inspection readiness. Evaluate records, regulatory commitments, and response plans.
  • Patient and supply impact. Confirm that critical information supports timely recalls, field actions, and continuity decisions.
Transform risk into insight
Discover how Crowe can help you enhance your internal audit readiness, governance, and strategy to stay ahead of evolving risks.

Plan your internal audit priorities with confidence

Work with experienced internal auditors who understand your industry’s unique risks and goals.
Contact us to explore how we can help strengthen your internal audit strategy for the year ahead.
Adam Pajakowski
Adam Pajakowski
Partner, Consulting,
Crowe Advisory LLC
Ryan McNally
Ryan McNally
Managing Director, Consulting,
Crowe Advisory LLC
Benjamin Newton
Benjamin Newton
Senior Manager, Consulting,
Crowe Advisory LLC

Related insights